A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors

Journal of Medicinal Chemistry

Volumn 46, Issue 14, 2003, Pages 3170-3173

  Sabatino, Giuseppina ^a   Chinol, Marco ^b   Paganelli, Giovanni ^b   Papi, Stefano ^b   Chelli, Mario ^c   Leone, Giuseppe ^a   Papini, Anna Maria ^a   De Luca, Angelo ^d   Ginanneschi, Mauro ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c ICCOM CNR   (Italy)

^d S Tau Indust Farmaceut R SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 10 [2 [6 [5 (HEXAHYDRO 2 OXO 1H THIENO[3,4 D]IMIDAZOL 4 YL) 1 PENTYLAMINO] 1 HEXYLAMINO] 2 OXOETHYL] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7 TRIACETIC ACID; BIOTIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DIAGNOSTIC VALUE; DRUG BINDING; DRUG CONJUGATION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS;

ANTINEOPLASTIC AGENTS; AVIDIN; BIOTIN; CHELATING AGENTS; DRUG STABILITY; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; ISOTOPE LABELING; NEOPLASMS; PROTEIN BINDING; RADIOPHARMACEUTICALS; YTTRIUM;

EID: 0038482100     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030789z     Document Type: Article

References (22)

1. 90Y-Biotin. Eur. J. Nucl. Med. 1999, 26, 348-357.
2. Fritzberg, A. R. Antibody pretargeted radiotherapy: A new approach and a second chance. J. Nucl. Med. 1998, 39, 20N-36N.
3. 90Y with negligible toxicity. Proc. Natl. Acad. Sci. 2000, 97, 1802-1807.
4. Magnani, P.; Paganelli, G.; Modorati, G.; Zito, F.; Songini, C.; Sudati, F.; Koch, P.; Maecke, H. R.; Brancato, R.; Siccardi, A. G.; Fazio, F. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J. Nucl. Med. 1996, 37, 967-971.
5. Goodwin, D. A. Tumor pretargeting: Almost the bottom line. J. Nucl. Med. 1995, 36, 876-879.
6. Chinol, M.; Grana, C.; Gennari, R.; Cremonesi, M.; Geraghty, J. G.; Paganelli, G. Pretargeted radioimmunotherapy of cancer. In Radioimmunotherapy of Cancer; Abrams, P. G., Fritzberg, A. R., Eds; Marcel Dekker: New York, 2000; pp 169-193.
7. 90Y-Biotin in glioma patients: Phase I study and preliminary therapeutic results. Cancer Biother. Radiopharm. 2001, 16, 227-235.
8. 1. Cancer Res. 1997, 57, 1922-1928.
9. Guttinger, M.; Guidi, F.; Chinol, M.; Reali, E.; Veglia, F.; Viale, G.; Paganelli, G.; Corti, A.; Siccardi, A. G. Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte tumor bridging. Cancer Res. 2000, 60, 4211-4215.
10. Pispa, J. Animal Biotinidase. Ann. Med. Exp. Biol. Fenn. 1965, 43 (Suppl. 5), 1-39.
11. Hymes, J.; Wolf, B. Biotinidase and its roles in Biotin metabolism. Clin. Chim. Acta 1996, 255, 1-11
12. Axworthy, D. B.; Theodore, L. J.; Gustavson, L. M.; Reno, J. M. Pretargeting methods and compounds, including radiolabeled biotins. PCT Int. Appl. WO93-25,240, 1993 (Chem. Abstr. 1994, 121, P30072j).
13. Wilbur, D. S.; Hamlin, D. K.; Pathare, P. M.; Weerawarna, S. A. Biotin reagents for antibody pretargeting. Synthesis, radioiodination, and in vitro evaluation of water soluble, biotinidase resistant Biotin derivatives. Bioconjugate Chem. 1997, 8, 572-584.
14. Foulon, C. F.; Alston, K. L.; Zalutsky, M. R. Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and [(5-iodo-3-pyridinyl)carbonyl]norbiotinamide: two radioiodinated Biotin conjugates with improved stability. Bioconjugate Chem. 1997, 8, 179-186.
15. Wilbur, D. S.; Hamlin, D. K.; Chyan, M. K.; Kegley, B. B.; Pathare, P. M. Biotin reagents for antibody pretargeting. 5. Additional studies of Biotin conjugate design to provide Biotinidase stability. Bioconjugate Chem. 2001, 12, 616-623.
16. Paganelli, G.; Magnani, P.; Siccardi, A. G.; Fazio, F. Clinical application of the avidin-Biotin system for tumor targeting. In Cancer Therapy with Radiolabeled Antibodies; Goldenberg, D. M., Ed.; CRC Press: Boca Raton, FL, 1995; pp 239-253.
17. Meyer, M.; Dahaoui-Gindrey, V.; Lecomte, C.; Guilard, R. Conformations and coordination schemes of carboxylate and carbamoyl derivatives of the teraazamacrocycles cyclen and cyclam, and the relation to their protonation states. Coord. Chem. Rev. 1998, 178-180, 1313-1405.
18. Lewis, M. R.; Raubitschek, A.; Shively, J. E. A facile, water soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specifity activity and high chelate stability in radiolabeled immunoconjugates. Bioconjugate Chem. 1994, 5, 565-576.
19. Lewis, M. R.; Kao, J. Y.; Anderson, A.-L. J.; Shively, J. E.; Raubitschek, A. An improved method for conjugating monoclonal Antibodies with N-hydroxysulfosuccinimidyl DOTA. Bioconjugate Chem. 2001, 12, 320-324.
20. Meyer, M.; Dahaoui-Gindfrey, V.; Lecomte, C.; Guilard, R. Conformations and coordination schemes of carboxylate and carbamoyl derivatives of the tetraazamacrocycles cyclen and cyclam, and the relation to their protonation states. Coord. Chem. Rev. 1998, 178, 1313-1405.
21. Feigl, F. Spot Tests in Organic Analysis; Elsevier: New York, 1966; p 251.
22. Cremonesi, M.; Ferrari, M.; Chinol, M.; Stabin, M. G.; Grana, C.; Prisco, G.; Robertson, C.; Tosi, G.; Paganelli, G. Three-step radioimmunotherapy with yttrium-90 Biotin: dosimetry and pharmacokinetics in cancer patients. Eur. J. Nucl. Med. 1999, 26, 110-120.